Company / Operating Income
Ultragenyx Pharmaceutical Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$535.0M
FY2025
5-year range
-$648.9M / -$424.2M
FY2021-FY2025
Trend
+0.2%
vs FY2024
Sector context
#189 of 204
Health Care
What the data says
Among 204 Health Care companies, Ultragenyx Pharmaceutical Inc. is in the bottom 7% for operating income. Operating Income has increased for 3 consecutive years, from -$649M in FY2022 to -$535M in FY2025.
Based on SEC 10-K filings.
-$535M in FY2025.
Improved from -$569M to -$535M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 204This company -$535.0M Sector average $107.7M
▼
-596.7% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s operating income has grown for 3 consecutive years.
- In FY2025, operating income increased 0.2% year-over-year.
- Ranks #189 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$535.0M | +0.2% |
| FY2024 | -$536.0M | +5.8% |
| FY2023 | -$569.0M | +12.3% |
| FY2022 | -$648.9M | -53.0% |
| FY2021 | -$424.2M | -14.2% |
| FY2020 | -$371.4M | -12.9% |
| FY2019 | -$328.9M | +11.4% |
| FY2018 | -$371.4M | -151.4% |
| FY2017 | -$147.7M | -160.2% |
| FY2016 | -$56.8M | +61.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026